The increase in cardiovascular risk of morbidity and mortality has been observed in patients with autoimmune diseases, including systemic lupus erythematosus (SLE)[@b1]. It has been proposed that systemic inflammation and autoimmune-related reactions play a pivotal role in the increase of cardiovascular risk. Endothelial damage and dysfunction mediated by the production of adhesion molecules and the overexpression of pro-inflammatory cytokines is regarded as an important consequence of autoimmune-related reactions[@b2][@b3]. Given that traditional Framingham risk factors[@b1] cannot represent the accelerated development of atherosclerosis in SLE patients[@b4], novel biomarkers for endothelial injury that proceed from clinical cardiovascular diseases are needed.

The detachment of endothelial cells from injured endothelium into circulation (circulating endothelial cell, CECs)[@b5] and the mobilization of endothelial progenitor cells (EPCs) from bone marrow[@b6] have been developed as biomarkers for vascular endothelial damage, the primary event in atherosclerosis. EPCs express endothelial \[vascular endothelial growth factor (VEGF) receptor-2\] and haematopoietic (CD34 and CD133) cell markers. During differentiation to mature EPCs, CD133 expression is lost and begins to express vascular endothelial (VE)-cadherin and von Willebrand factor[@b7]. The level of circulating EPCs has been shown to be inversely correlated with cardiovascular risk[@b8]. The levels of CECs and the amount of apoptotic CECs has been reported as representing the extent of endothelial damage[@b9][@b10].

Pro-angiogenic factors, such as VEGF, can mobilize EPCs and recruit EPCs to the injured endothelial lesion[@b11]. By contrast, anti-angiogenic factors exert an opposite effect. Several pro-inflammatory and immunosupressor cytokines, such as Interleukin-1β (IL-1β) [@b12], IL-6[@b13], IL-17[@b14], TGF-β[@b15], and interferon-α (IFN-α)[@b16][@b17], are involved in EPC mobilization, recruitment, proliferation and function. Most of these cytokines have been reported to be deregulated in autoimmune patients and may involve immune-mediated mechanisms in vascular damage.

In the present work, we measured the amounts of circulating EPCs, CECs and apoptotic CECs in SLE patients in a clinical trial that evaluated the effect of adding a Chinese medicinal herb to the standard therapy. We also evaluated the possible correlations between treatment outcome and serum levels of cytokines relevant for SLE.

Methods
=======

Patients and Blood Sampling
---------------------------

The study protocol was approved by the Institutional Review Board and Ethics Committee of Chang Gung Memorial Hospital, Linkou, Taiwan. The study was performed in accordance with the approved guidelines. The informed consent was obtained from all subjects. The clinical trial was registered with number ISRCTN81818883 from November 2007 to October 2010, 85 SLE patients were screened via rheumatology clinics, and 62 of them were enrolled into the trial; 31 patients were randomized into a placebo group and another 31 patients into an LC group. The LC formula was designed to combine the contents of an L (Long Dan Xie Gan Tang) and C (Zhi Bai Di Huang Wan) regimen. LC was given orally for 16 weeks and withdrawn for 8 weeks, and the evaluations were performed every 4 weeks. Adequate peripheral blood samples with satisfied quality for assessment were obtained from 28 patients in the placebo group and 29 in the LC group every 4 weeks before, during and after treatment. These blood samples were subjected to measurement of serum circulating EPCs, CECs, apoptotic CECs and soluble factors, including IFN-α, IL-1β, IL-6, IL-18 and VEGF.

Flow Cytometry
--------------

To measure circulating EPCs and CECs, a method from Duda *et al*.[@b18] was adapted with modifications as in our previous study[@b19]. Flow cytometry was used for whole blood analysis without enrichment procedures to avoid manipulation artifacts. The EPCs were characterized as CD31^+^ VEGFR-2^+^ CD45^dim^ CD133^+^; mature CECs were defined as CD31^Bright^ VEGFR-2^+^ CD45^-^ CD133^-^. The chromophores conjugated with specific antibodies used in this study included CD31-FITC (BD Pharmingen, San Diego, CA), CD133-PE (Miltenyi Biotec, Auburn, CA), CD45-PerCP (BD Pharmingen), and VEGFR2-PE (R&D Systems, Minneapolis, MN). For apoptotic CECs, AAD-7 was also applied to stain the apoptotic CECs. During the analysis of flow cytometry data, the mononuclear cell population was gated to avoid RBC, platelet, cell debris, and neutrophil contamination; 100,000 events in the gated population were collected by a FACScaliber flow cytometer (BD Biosciences, San Jose, CA, USA). The acquisition data were collected and analyzed using CellQuest Software (BD Biosciences).

Measurement of serum cytokines
------------------------------

Serum levels of proinflammatory and angiogenic factors were quantified by a sandwich enzyme-linked immunosorbent assay (ELISA). VEGF was measured using the Duoset ELISA kits from R&D Systems (Wiesbaden, Germany). IFN-α, IL-1β, IL-6, and IL-18 were measured using Quantikine ELISA kits (R&D Systems) according to the manufacturer's instructions.

Statistical analysis
--------------------

Statistical analyses were performed using the software package SPSS 18 (SPSS, Chicago, IL). Linear mixed model was applied to compare the disease activity of SLE (SLEDAI score) score, circulating endothelial cell and blood biochemistry between groups. *p* \< 0.05 was considered significant.

Results
=======

Characteristics of patients
---------------------------

Among enrolled patients, the clinical parameters showed a higher disease activity in LC group in terms of the SLEDAI score, C3, C4 and anti-dsDNA antibody before treatment (unpublished data). The significant reduction in the administered dosage of steroids was noted in the LC group (unpublished data).

Dynamic changes in CECs, EPCs and apoptotic CECs
------------------------------------------------

To examine the correlation between clinical outcomes and serological markers, the quantities of serum cytokines, EPCs, CECs and apoptotic CECs were serially estimated. The representative result of flow cytometric analysis for EPCs, CECs and apoptotic CECs was demonstrated in [Fig. 1](#f1){ref-type="fig"}. As shown in [Fig. 2A](#f2){ref-type="fig"}, the proportion of EPCs at pretreatment levels in the placebo group increased from the beginning to the end of trial (*p* \< 0.05). It was further elevated 8 weeks after withdrawal of the standard treatment. Intriguingly, the EPCs ratio of LC group remained stationary during the entire observation period, including that after withdrawal of standard treatment. The CEC ratio in placebo group exhibited an increasing trend (not significantly different, *p* = 0.172) with marked elevation at weeks 4 and 16 during the standard treatment. The final CEC ratio at week 24 (8 weeks after treatment) in the placebo group remained higher than the pretreatment ratio. In the LC group, the CEC ratio was elevated at week 4 followed by a continuous decline to the end, close to the pre-treatment ratio. The apoptotic CEC ratio had an increasing trend (not significantly different, *p* = 0.211) in both groups, but the extent in the LC group was less than the placebo group.

Profiles of serum cytokine levels
---------------------------------

We next examined the serial changes in serum levels of IL-18, VEGF, IFN-α, IL-1β, and IL-6. Before beginning treatment, the serum levels of IL-18 were higher in the LC group, which was compatible with clinical SLEDAI scores for disease activity. After treatment, the IL-18 levels of the placebo and LC groups became similar at the 2^nd^ month of standard treatment and, furthermore, the levels of IL-18 declined to levels lower than the placebo group (not significantly different, p  = 0.190). Serum levels of VEGF, exhibited a similar profile as IL-18. No significant alteration was noted in serum levels of IL-18, VEGF, IFN-α, IL-1β and IL-6 ([Fig. 3](#f3){ref-type="fig"}).

Discussion
==========

In SLE patients receiving the standard treatment, we found that levels of endothelial injury biomarkers incremented during the standard treatment and these markers, as well as serum levels of VEGF and IL-18, could be suppressed by a combinatory treatment with Chinese medicinal herb LC.

Disease-modifying antirheumatic drugs (DMARDs) are used as a prevention to reduce the incidence of flares from the disease and lower the need for steroid use. Antimalarial agents, such as hydroxychloroquine[@b20] and immunosuppressants are commonly used as DMARDs. DMARDs are regarded as a part of the standard treatments for autoimmune disease. Their use during pregnancy can prevent flares of the disease compromising the health of the mother and fetus[@b21]. Our results from a randomized placebo-controlled clinical trial show that LC could reduce the needed dose of steroid during standard treatment of SLE (unpublished data). Thus, LC might have the potential to be developed as a novel DMARD. The biomarker data of the present study further provides a correlation between endothelial injury and the effect of LC on SLE patients.

It has been demonstrated that autoimmune reactions enhanced the release of bone marrow progenitor cells, which include EPCs, in patients with SLE[@b14]. The number of circulating EPCs in active SLE patients was not significantly different from healthy controls, but their functions were partly impaired, including proliferation, adhesion, migration, and tube formation[@b22]. EPCs are a heterogeneous population whose physiological role is to carry out angiogenesis and vascular repair[@b23]. Because of their potential role in vascular repair, the amount of circulating EPCs is considered a surrogate marker for vascular dysfunction and cardiovascular risk, and thus a promising tool in cell therapy for cardiovascular diseases, especially in connective tissue diseases.

In addition to changes in cellular profiles, several cytokines, such as proinflammatory cytokines and VEGF, involve vascular damage and angiogenesis. We demonstrated that elevated VEGF and IL-18 levels, but not IFN-α, IL-1β or IL-6 levels, were suppressed by the LC treatment in SLE patients. Serum levels of IL-18, an inflammosome activator, were shown to be elevated in SLE and correlated with EPC/circulating angiogenic cell (CACs) dysfunction. In *ex vivo* cultures of EPCs/CACs from SLE patients, exogenous IL-18 inhibited endothelial differentiation and neutralization of IL-18 could restore their differentiation into endothelial cells[@b24]. It suggests a correlation between the biological effects of IL-18 and the impaired vascular repair *in vivo*. Our clinical results showing that LC treatments reduced the needed steroid dosage and suppressed the level of IL-18 may provide a line of evidence for this correlation.

The current development of biological markers for vascular damage and angiogenesis in SLE are mainly from investigations focusing on the correlation between these biomarkers, disease activity and related cardiovascular complications[@b25]. Given EPCs mobilized from bone marrow may facilitate non-physiological angiogenesis and resultant unfavorable vascular events; EPCs could be regarded as treatment targets for SLE. On the other hand, our findings that LC treatments reduced the amount of EPCs during standard steroid therapy may imply that the effect of LC is to target EPCs. Surely, this assumption needs further validation by both *in vitro* and *in vivo* experiments. By current data, we may have no adequate evidence to differentially suggest the alterations in biomarkers of endothelial injury are direct effects of LC or a steroid-sparing effect.

In conclusion, the levels of endothelial injury biomarkers, as well as VEGF and IL-18, in SLE patients during standard treatment could be suppressed by a combinatory treatment with the traditional Chinese medicine LC.
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![Representative data for flow cytometric analysis of EPC, CEC and apoptotic CEC.\
(**A**) Dot plot shows the gating strategy used to exclude debris; (**B**) The EPCs were characterized as CD31^+^ VEGFR-2^+^ CD45^dim^ CD133^+^; (**C**) The CECs were defined as CD31^Bright^ VEGFR-2^+^ CD45^−^ CD133^−^; (**D**) AAD-7 staining was used for identification and quantification of apoptotic CECs.](srep19622-f1){#f1}

![Serial changes in the amounts of EPCs, CECs and apoptotic CECs.\
(**A**) EPC; (**B**) CEC; (**C**) apoptotic CEC. The ratios of EPC, CEC and apoptotic CEC were calculated by comparing pretreatment amounts of these cell populations of each own subject. \**p* \<0.05.](srep19622-f2){#f2}

![Serum levels of cytokines in SLE patients.\
(**A**) VEGF; (**B**) IL-18; (**C**) IL-1β; (**D**) IL-6; E, IFN-α.](srep19622-f3){#f3}
